Restrictive cardiomyopathy due to light chain amyloidosis. Post CYBORD improvement.

Authors

  • Zuilma Yurith Vasquez Ortiz National Institute of Medical Science and Nutrition Salvador Zuviran
  • Adriana E. Viñas Mendieta Marine Medical Center "Cirujano Santiago Tavara"
  • Rolando D. Ramirez Cervantes National Institute of Medical Sciences and Nutrition Salvador Zubiran
  • Sandra Rosales Uvera National Isntitute of Medical Sciences and Nutrition Salvador Zubiran
  • Maria Jose LIzardo National Institute of Medical Sciences and Nutrition Salvador Zubiran

DOI:

https://doi.org/10.37615/retic.v5n3a7

Keywords:

amiloidosis, echocardiography, heart failure

Abstract

AL cardiac amyloidosis is a disease caused by extracellular deposition of insoluble proteins; Without treatment, survival is usually less than six months after the onset of symptoms of heart failure. The CYBORD-D scheme is the first choice for its safety and favorable evolution. We present the case of a patient with AL amyloidosis with symptoms of severe cardiac and extracardiac dysfunction, also with all laboratory and echocardiographic parameters of poor prognosis. At one year of follow-up, after eight cycles of the CYBORD regimen, presented great clinical improvement, complete hematological response, decrease in cardiac biomarkers and favorable progress in cardiac function.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management - ScienceDirect. Accessed April 8, 2022. https://www.sciencedirect.com/science/article/pii/S2666087319300134

Kourelis TV, Kyle RA, Dingli D, et al. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clin Proc. 2017;92(6):908-917. doi: https://doi.org/10.1016/j.mayocp.2017.02.016 DOI: https://doi.org/10.1016/j.mayocp.2017.02.016

Morgan GJ, Kelly JW. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains. J Mol Biol. 2016;428(21):4280-4297. doi: https://doi.org/10.1016/j.jmb.2016.08.021 DOI: https://doi.org/10.1016/j.jmb.2016.08.021

Fine NM, Davis MK, Anderson K, et al. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. Can J Cardiol. 2020;36(3):322-334. doi: https://doi.org/10.1016/j.cjca.2019.12.034 DOI: https://doi.org/10.1016/j.cjca.2019.12.034

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases | European Heart Journal | Oxford Academic. Accessed April 9, 2022. https://academic.oup.com/eurheartj/article/42/16/1554/6212698?login=false DOI: https://doi.org/10.1093/eurheartj/ehab072

Lee Chuy K, Drill E, Yang JC, et al. Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis. JACC CardioOncology. 2020;2(2):223-231.doi: https://doi.org/10.1016/j.jaccao.2020.05.012 DOI: https://doi.org/10.1016/j.jaccao.2020.05.012

Salinaro F, Meier-Ewert HK, Miller EJ, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J - Cardiovasc Imaging. 2017;18(9):1057-1064. doi: https://doi.org/10.1093/ehjci/jew298 DOI: https://doi.org/10.1093/ehjci/jew298

Clemmensen TS, Eiskjær H, Ladefoged B, et al. Prognostic implications of left ventricular myocardial work indices in cardiac amyloidosis. Eur Heart J - Cardiovasc Imaging. 2021;22(6):695-704. doi: https://doi.org/10.1093/ehjci/jeaa097 DOI: https://doi.org/10.1093/ehjci/jeaa097

Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107(10):3854-3858. doi: https.//doi.org/10.1182/blood-2005-11-4385 DOI: https://doi.org/10.1182/blood-2005-11-4385

Downloads

Published

2022-12-31

How to Cite

1.
Vasquez Ortiz ZY, Viñas Mendieta AE, Ramirez Cervantes RD, Rosales Uvera S, Jose LIzardo M. Restrictive cardiomyopathy due to light chain amyloidosis. Post CYBORD improvement. Rev Ecocardiogr Pract Otras Tec Imag Card (RETIC) [Internet]. 2022 Dec. 31 [cited 2024 Nov. 21];5(3):31-6. Available from: https://imagenretic.org/RevEcocarPract/article/view/493

Issue

Vol. 5 No. 3 (2022): Journal of Practical Echocardiography and Other Cardiac Imaging Techniques

Section

CLINICAL CASES

License

Copyright (c) 2022 Zuilma Yurith Vasquez Ortiz, Adriana E. Viñas Mendieta, Rolando D. Ramirez Cervantes, Sandra Rosales Uvera, Maria Jose Lizardo

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

RETIC is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license https://creativecommons.org/licenses/by-nc-nd/4.0 which allows sharing, copying and redistribution of the material in any medium or format, under the following terms:

  • Attribution: you must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests that the licensor endorses you or your use.
  • Non-commercial: you may not use the material for commercial purposes.
  • No Derivatives: if you remix, transform or build upon the material, you may not distribute the modified material.
  • No Additional Restrictions: you may not apply legal terms or technological measures that legally restrict others from doing anything permitted by the license.
Crossref
Scopus
Google Scholar
Europe PMC